Purchase this article with an account.
Scott D. Schoenberger, Stephen J. Kim, Jinsong Sheng, Kasra A. Rezaei, Maziar Lalezary, Edward Cherney; Increased Prostaglandin E2 (PGE2) Levels in Proliferative Diabetic Retinopathy, and Correlation with VEGF and Inflammatory Cytokines. Invest. Ophthalmol. Vis. Sci. 2012;53(9):5906-5911. doi: https://doi.org/10.1167/iovs.12-10410.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We determined vitreous levels of prostaglandin E2 (PGE2), VEGF, and 15 other cytokines in diabetic and nondiabetic patients undergoing vitrectomy.
Of 26 eyes of 26 patients enrolled consecutively, 13 eyes underwent vitrectomy for complications related to proliferative diabetic retinopathy, and the other 13 for epiretinal membrane, macular hole, vitreous opacities, or dislocated intraocular lens. Undiluted vitreous samples were taken at the time of surgery and frozen immediately at −80°C, and later analyzed for PGE2, VEGF, and 15 other cytokines.
PGE2 levels were 53% higher in diabetic eyes. Mean ± standard deviation PGE2 levels were 25.11 ± 11 pg/mL and 16.40 ± 7 pg/mL in diabetic and nondiabetic eyes, respectively (P < 0.03). Mean ± standard deviation VEGF levels were 2225 ± 3798 pg/mL and 66 ± 185 pg/mL in diabetic and nondiabetic eyes, respectively (P < 0.001). Other cytokines, including eotaxin-1, growth related oncogene (GRO), interleukin (IL)-6, IL-8, interferon-γ-inducible protein of 10 kDa (IP-10), monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor alpha (TNF-α), and platelet-derived growth factor-AA, also were elevated significantly in diabetic eyes. A significant correlation was seen between PGE2 levels and IP-10 and VEGF (P = 0.04).
PGE2 levels are significantly higher in the vitreous of patients with complications from proliferative diabetic retinopathy, and correlate with IP-10 and VEGF. The results of our study suggest that PGE2 may have a pathogenic role in diabetic retinopathy and implicates a potential therapeutic role for nonsteroidal anti-inflammatory drugs. (ClinicalTrials.gov number, NCT01609881.)
This PDF is available to Subscribers Only